{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T05:47:59Z","timestamp":1768888079734,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2022.12.033","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T08:27:36Z","timestamp":1673598456000},"page":"A79-A84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned"],"prefix":"10.1016","volume":"41","author":[{"given":"Ahmet","family":"Afsar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apoorva","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul Aziz Garba","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veh Kesse Fabien","family":"Diomande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00ebl","family":"Maufras du Ch\u00e2tellier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fazal","family":"Ather","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.12.033_b0005","unstructured":"Technical Guidance, mOPV2 management, monitoring, removal and disposal. GPEI, May 2020. http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/05\/mOPV2-Technical-Guidance-20200525.pdf. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0010","unstructured":"Standard Operating Procedures for responding to a poliovirus event or outbreak v3.1, GPEI, March 2020. http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/04\/POL-SOP-V3.1-20200424.pdf. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0015","unstructured":"Sabin monovalent oral polio vaccine type 2 (mopv2) vaccine request form, Version 3. GPEI, April 2020. http:\/\/polioeradication.org\/wp-content\/uploads\/2020\/07\/mOPV2-Vaccine-Request-Form-template-april-2020-ENG-v1.4.doc. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0020","unstructured":"Vaccine Arrival Report (VAR) completion guideline. UNICEF Supply Division; 2017. https:\/\/www.unicef.org\/spanish\/supply\/files\/VAR_English-with_VaxAlert_and_Qtag_instr.pdf. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0025","unstructured":"Effective Vaccine Management Standard Operating Procedures (EVM\/SOPs). https:\/\/www.who.int\/immunization\/programmes_systems\/supply_chain\/EVM_model_SOP_manual_EN_June_2013_compact.pdf. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0030","unstructured":"Temperature sensitivity of vaccines, WHO\/IVB\/06.10. WHO; 2006. https:\/\/apps.who.int\/iris\/handle\/10665\/69387. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0035","unstructured":"Summary of stability data for licensed vaccines, PATH, Seattle, November 2019. https:\/\/path.azureedge.net\/media\/documents\/TS_vaccine_stability_table.pdf. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0040","unstructured":"Effective Vaccine Management (EVM) Global Data Analysis 2009-2016, WHO November 2017. https:\/\/www.who.int\/immunization\/programmes_systems\/supply_chain\/EVM-Global-Data-Analysis-2010-2016-EN.pdf?ua=1. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0045","unstructured":"tOPV disposal guideline (Waste management of tOPV-Selecting Methods for the Destruction of Trivalent Oral Polio Vaccine (tOPV) during the switch), WHO, February 2016. . Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0050","unstructured":"Guidelines for Safe Disposal of Unwanted Pharmaceuticals in and after Emergencies WHO; 1999. https:\/\/www.who.int\/water_sanitation_health\/medicalwaste\/unwantpharm.pdf. Accessed 20 November 2020."},{"key":"10.1016\/j.vaccine.2022.12.033_b0055","unstructured":"Safe management of wastes from health-care activities \/ edited by Y. Chartier et al. \u2013 2nd ed.; 2014. https:\/\/www.who.int\/water_sanitation_health\/publications\/wastemanag\/en\/. Accessed 20 November 2020."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22015584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:36Z","timestamp":1759404336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22015584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":11,"alternative-id":["S0264410X22015584"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.033","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.12.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}